Background: Lung cancer is the most common cancer worldwide. Evidence suggests self-
management (SM) interventions benefit cancer patients. This review aims to determine the …

Background The objective of this study was to describe the real-world treatment and overall
survival (OS) of German patients with a diagnosis of advanced non-small cell lung cancer …

Objective: To describe the cost-effectiveness of pembrolizumab plus chemotherapy
(carboplatin and paclitaxel or nab-paclitaxel; P+ C) in metastatic, squamous, non-small-cell …

Purpose Treatments for advanced non-small cell lung cancer (NSCLC) have evolved to
include targeted and immuno-oncology therapies, which have demonstrated clinical benefits …

Aim: This analysis aimed to evaluate the cost–effectiveness of pembrolizumab monotherapy
as first-line treatment in advanced non-small-cell lung cancer patients with a programmed …

Background In estrogen receptor–positive metastatic breast cancer, ESR1 mutations (ESR1
m) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh) …

Non-small cell lung cancer is a major sub-type of lung cancer that is associated with a poor
diagnosis resulting in poor therapy for the disorder. In order to achieve a better prognosis …

The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC)
has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The …

There is accumulating evidence that anemia and iron deficiency, thrombocytopenia, blood
loss and coagulopathy are independent risk factors for adverse patient outcomes in …

Objective. Novel therapeutics and supportive care improved outcomes for metastatic non‐
small‐cell lung cancer (mNSCLC) patients. Major advances over the past five decades …